Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589956807> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2589956807 endingPage "LBA4511" @default.
- W2589956807 startingPage "LBA4511" @default.
- W2589956807 abstract "LBA4511 Background: Interleukin-2 (IL2), used to treat MRCC, is not known to improve survival. To assess this potential benefit, the French Immunotherapy Intergroup designed a multicenter trial for patients (pts) with intermediate prognosis for response to cytokine treatment (Negrier et al NEJM 1998). Methods: Untreated pts with more than one metastatic site and Karnofsky score ≥80 were randomized to medroxyprogesterone (MPA: control group), α-Interferon (IFN), sc IL2 or IFN+sc IL2 in a 2x2 factorial design. Patients were evaluated after 3 months; pts without progression continued treatment for up to 6 months. The primary endpoint was overall survival (OS). The planned sample size was 456 pts based on a minimum expected difference of 10% in OS at 2 years with 5% α error and 80% power. Intent-to-treat analysis was planned 6 months after last enrollment. OS analysis (1 interaction check test and 2 log-rank tests) will be performed after α-level adjustment to maintain overall α risk at 0.05. Results: From January 00 to July 04, 492 pts were randomized: 123 to MPA, 122 to IFN, 125 to IL2 and 122 to IFN+IL2. Patient characteristics were well balanced between the groups. Median age was 61 years, 75% were males, Karnofsky score was ≥ 90 in 61%, 96% had nephrectomy, time from initial diagnosis to metastases was > 1 year in 34%. A total of 11 vs. 60 vs. 127 vs. 181 grade 3/4 toxic events were observed in the MPA, IFN, IL2 and IFN+IL2 groups, respectively; no toxic death occurred. Response rates (WHO criteria) at 3 months in the 4 groups were 2.6, 4.4, 5.1 and 10.4% respectively. Current median follow up is 28 months. OS will be analyzed in January 05. Conclusions: This study will establish whether cytokines improve OS in MRCC pts with intermediate prognosis. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche" @default.
- W2589956807 created "2017-03-03" @default.
- W2589956807 creator A5002114271 @default.
- W2589956807 creator A5019588141 @default.
- W2589956807 creator A5040832651 @default.
- W2589956807 creator A5049672639 @default.
- W2589956807 creator A5057708685 @default.
- W2589956807 creator A5059071612 @default.
- W2589956807 creator A5069166380 @default.
- W2589956807 creator A5069761611 @default.
- W2589956807 creator A5076354847 @default.
- W2589956807 creator A5085315048 @default.
- W2589956807 date "2005-06-01" @default.
- W2589956807 modified "2023-09-23" @default.
- W2589956807 title "Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial" @default.
- W2589956807 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.lba4511" @default.
- W2589956807 hasPublicationYear "2005" @default.
- W2589956807 type Work @default.
- W2589956807 sameAs 2589956807 @default.
- W2589956807 citedByCount "64" @default.
- W2589956807 countsByYear W25899568072012 @default.
- W2589956807 countsByYear W25899568072013 @default.
- W2589956807 countsByYear W25899568072014 @default.
- W2589956807 countsByYear W25899568072015 @default.
- W2589956807 countsByYear W25899568072020 @default.
- W2589956807 crossrefType "journal-article" @default.
- W2589956807 hasAuthorship W2589956807A5002114271 @default.
- W2589956807 hasAuthorship W2589956807A5019588141 @default.
- W2589956807 hasAuthorship W2589956807A5040832651 @default.
- W2589956807 hasAuthorship W2589956807A5049672639 @default.
- W2589956807 hasAuthorship W2589956807A5057708685 @default.
- W2589956807 hasAuthorship W2589956807A5059071612 @default.
- W2589956807 hasAuthorship W2589956807A5069166380 @default.
- W2589956807 hasAuthorship W2589956807A5069761611 @default.
- W2589956807 hasAuthorship W2589956807A5076354847 @default.
- W2589956807 hasAuthorship W2589956807A5085315048 @default.
- W2589956807 hasConcept C10515644 @default.
- W2589956807 hasConcept C121608353 @default.
- W2589956807 hasConcept C126322002 @default.
- W2589956807 hasConcept C126894567 @default.
- W2589956807 hasConcept C141071460 @default.
- W2589956807 hasConcept C168563851 @default.
- W2589956807 hasConcept C203092338 @default.
- W2589956807 hasConcept C204243189 @default.
- W2589956807 hasConcept C2776907518 @default.
- W2589956807 hasConcept C2777472916 @default.
- W2589956807 hasConcept C2777701055 @default.
- W2589956807 hasConcept C66339696 @default.
- W2589956807 hasConcept C71924100 @default.
- W2589956807 hasConcept C90924648 @default.
- W2589956807 hasConceptScore W2589956807C10515644 @default.
- W2589956807 hasConceptScore W2589956807C121608353 @default.
- W2589956807 hasConceptScore W2589956807C126322002 @default.
- W2589956807 hasConceptScore W2589956807C126894567 @default.
- W2589956807 hasConceptScore W2589956807C141071460 @default.
- W2589956807 hasConceptScore W2589956807C168563851 @default.
- W2589956807 hasConceptScore W2589956807C203092338 @default.
- W2589956807 hasConceptScore W2589956807C204243189 @default.
- W2589956807 hasConceptScore W2589956807C2776907518 @default.
- W2589956807 hasConceptScore W2589956807C2777472916 @default.
- W2589956807 hasConceptScore W2589956807C2777701055 @default.
- W2589956807 hasConceptScore W2589956807C66339696 @default.
- W2589956807 hasConceptScore W2589956807C71924100 @default.
- W2589956807 hasConceptScore W2589956807C90924648 @default.
- W2589956807 hasIssue "16_suppl" @default.
- W2589956807 hasLocation W25899568071 @default.
- W2589956807 hasOpenAccess W2589956807 @default.
- W2589956807 hasPrimaryLocation W25899568071 @default.
- W2589956807 hasRelatedWork W1512088449 @default.
- W2589956807 hasRelatedWork W2113780394 @default.
- W2589956807 hasRelatedWork W2144031118 @default.
- W2589956807 hasRelatedWork W2244282381 @default.
- W2589956807 hasRelatedWork W2414338203 @default.
- W2589956807 hasRelatedWork W2584850773 @default.
- W2589956807 hasRelatedWork W2998663103 @default.
- W2589956807 hasRelatedWork W3129944423 @default.
- W2589956807 hasRelatedWork W3141563927 @default.
- W2589956807 hasRelatedWork W4244069386 @default.
- W2589956807 hasVolume "23" @default.
- W2589956807 isParatext "false" @default.
- W2589956807 isRetracted "false" @default.
- W2589956807 magId "2589956807" @default.
- W2589956807 workType "article" @default.